Chronic non-atrophic erosive gastritis
Conditions
Interventions
Group A:teprenone
Group B:none
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. 18-65y; 2. Have been diagnosed as chronic non-atrophic erosive gastritis by endoscopy within 1 weeks before enrollment, and the modified Lanza score >=2; 3. Have at least two symptoms in four majorm symptoms (epigastric pain, epigastric burning, early satiety, belching) and total sympto score >=4 (Rome III for Functional Gastrointestinal Disorders).
Exclusion criteria
Exclusion criteria: 1. Suspected upper gastrointestinal malignancy by endoscopy; 2. Peptic ulcer and bleeding by endoscopy; 3. Severe cardiac, hepatic or renal insufficiency,Severe neurological or psychological disease; 4. Pregnant or lactating women; 5. Have taken drugs which may affect evaluating the efficacy of study drug within two weeks before enrollment (includes but not limits to: PPIs such as omeprazole, rabeprazole, pantoprazole, lansoprazole, esomeprazole, H2 receptor antagonists such as cimetidine, ranitidine, famotidine, antacids such as calcium carbonate, gastric mucosal protectants such as colloidal bismuth potassium citrate and other bismuth products, sulcralfate, aluminum phosphate, teprenone, gefarnate, aluminum magnesium carbonate, glutamine, rebamipide, ecabet, misoprostol, antibiotics such as amoxicillin, clarithromycin, tetracycline, ofloxacin, levofloxacin, furazolidone, metronidazole, tinidazole, NSAIDs such as aspirin, ibuprofen, loxoprofen, naproxen, diclofenac, indomethacin, meloxicam, acetaminophen); 6. History of allergic reaction to the medications used in this study; 7. Patients that investigators consider ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference of the modified Lanza score after 4 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference of patients’ gastric mucosal concentration of hexosamine, PGE2 and HSP70 after 4 week;The difference of total effective rate after 8 weeks treatment evaluated by endoscopy;The difference of total effective rate after 4 and 8 weeks treatment evaluated by clinical symptoms;The difference of total effective rate after 4 weeks treatment evaluated by histologic examination; | — |
Countries
China
Contacts
Public ContactZhaoshen Li
Outcome results
None listed